SK56496A3 - 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use - Google Patents

5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use Download PDF

Info

Publication number
SK56496A3
SK56496A3 SK564-96A SK56496A SK56496A3 SK 56496 A3 SK56496 A3 SK 56496A3 SK 56496 A SK56496 A SK 56496A SK 56496 A3 SK56496 A3 SK 56496A3
Authority
SK
Slovakia
Prior art keywords
thienyl
group
mmol
substituted
vacuo
Prior art date
Application number
SK564-96A
Other languages
English (en)
Slovak (sk)
Inventor
Lenz S Moltzen
Erik Falch
Klaus P Bogeso
Povl Krogsgaard-Larsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SK56496A3 publication Critical patent/SK56496A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK564-96A 1993-11-03 1994-11-02 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use SK56496A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK931243A DK124393D0 (da) 1993-11-03 1993-11-03 Compounds
PCT/DK1994/000411 WO1995012587A1 (en) 1993-11-03 1994-11-02 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Publications (1)

Publication Number Publication Date
SK56496A3 true SK56496A3 (en) 1996-12-04

Family

ID=8102626

Family Applications (1)

Application Number Title Priority Date Filing Date
SK564-96A SK56496A3 (en) 1993-11-03 1994-11-02 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use

Country Status (17)

Country Link
EP (2) EP0726896A1 (da)
JP (1) JPH09504531A (da)
KR (1) KR960705797A (da)
CN (1) CN1056837C (da)
AU (1) AU680062B2 (da)
CA (1) CA2175685A1 (da)
CZ (1) CZ127296A3 (da)
DK (1) DK124393D0 (da)
FI (1) FI961872A (da)
HU (1) HUT74692A (da)
NO (1) NO306159B1 (da)
NZ (1) NZ275088A (da)
PL (1) PL314182A1 (da)
RU (1) RU2138488C1 (da)
SK (1) SK56496A3 (da)
WO (1) WO1995012587A1 (da)
ZA (1) ZA948631B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2212836C (en) * 1995-02-13 2003-08-12 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
UA52698C2 (uk) * 1996-10-04 2003-01-15 Х. Луннбек А/С Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
IT1318636B1 (it) * 2000-07-21 2003-08-27 Roberto Pellicciari Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato.
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
CN1863810B (zh) 2003-04-09 2010-12-01 惠氏公司 [2-(8,9-二氧代-2,6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
EA014233B1 (ru) * 2006-06-08 2010-10-29 Эли Лилли Энд Компани Замещенные карбоксамиды

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69102816T2 (de) * 1990-05-11 1995-03-16 Sankyo Co Piperdinyloxy- und Chinindidinyloxy- isoxazol- Derivate, ihre Herstellung und ihre therapeutische Verwendung.
DE69325662T2 (de) * 1992-10-23 2000-02-10 Merck Sharp & Dohme Ltd., Hoddesdon Dopamin rezeptor subtyp liganden

Also Published As

Publication number Publication date
CN1056837C (zh) 2000-09-27
KR960705797A (ko) 1996-11-08
FI961872A0 (fi) 1996-05-02
ZA948631B (en) 1995-07-10
DK124393D0 (da) 1993-11-03
NO961783D0 (no) 1996-05-02
EP0994107A1 (en) 2000-04-19
RU2138488C1 (ru) 1999-09-27
CA2175685A1 (en) 1995-05-11
JPH09504531A (ja) 1997-05-06
HUT74692A (en) 1997-01-28
PL314182A1 (en) 1996-09-02
AU8057994A (en) 1995-05-23
CZ127296A3 (en) 1996-09-11
HU9601167D0 (en) 1996-07-29
CN1136810A (zh) 1996-11-27
WO1995012587A1 (en) 1995-05-11
NO306159B1 (no) 1999-09-27
NZ275088A (en) 1997-08-22
EP0726896A1 (en) 1996-08-21
AU680062B2 (en) 1997-07-17
FI961872A (fi) 1996-05-03
NO961783L (no) 1996-06-25

Similar Documents

Publication Publication Date Title
JP6861858B2 (ja) Ssao阻害剤
KR100776119B1 (ko) 트리아졸 유도체
KR101733180B1 (ko) 신규 1-아릴-3-아자바이사이클로[3.1.0]헥산:제조 방법 및 신경 정신 질환 치료를 위한 용도
WO2002006237A1 (fr) Medicament comprenant un derive de dicyanopyridine
JP5892550B2 (ja) 縮合イミダゾール誘導体
US6200999B1 (en) 3-Alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds
WO2003070712A1 (en) Thioibotenic acid and derivatives thereof
SK56496A3 (en) 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds, pharmaceutical composition containing them and their use
JP6748123B2 (ja) サクビトリルカルシウム塩
JP6231621B2 (ja) 新規ベンゾアゼピン誘導体及びその医薬用途
EP2349308A1 (en) Compounds for treatment of alzheimer's disease
CA2725425A1 (en) Homocysteine synthase inhibitor
JP3354258B2 (ja) 新規なインドール類またはその塩
KR100832750B1 (ko) N-페닐아마이드 유도체를 함유하는 허혈성 질환의 예방또는 치료용 조성물
KR20190126525A (ko) 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
JP4172895B2 (ja) ヘテロジアジノン誘導体